Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 2, 2014, Pages 70-76

  Hanaoka, Hirofumi ^a   Kuroki, Masahide ^b   Yamaguchi, Aiko ^a   Achmad, Arifudin ^a   Iida, Yasuhiko ^a   Higuchi, Tetsuya ^a   Oriuchi, Noboru ^a   Tsushima, Yoshito ^a   Endo, Keigo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

CEA; fractionation of doses; fully human antibody; radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; COLON TUMOR; DRUG SCREENING; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; RADIOIMMUNOTHERAPY; RANDOMIZATION; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 84894094185     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2013.1562     Document Type: Article

References (32)

1. Witzig TE, Molina A, Gordon LI, et al. Long-Term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium-90 ibritumomab tiuxetan. Cancer (.2007);109:1804.
2. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with lowgrade and transformed non-Hodgkin's lymphomas. J Clin Oncol (.2005);23:7565.
3. Kodera Y, Isobe K, Yamauchi M, et al. Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation. Br J Cancer (.1993);68:130.
4. Hammarstrom S. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol (.1999);9:67.
5. Juweid M, Sharkey RM, Behr T, et al. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res (.1995);55:5946s.
6. Wong JYC, Chu DZ, Yamauchi DM, et al. A phase I radioimmunotherapy trial evaluating 90Yttrium-labeled anticarcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res (.2000);6:3855.
7. Koppe MJ, Oyen WJ, Bleichrodt RP, et al. Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biother Radiopharm (.2006);21:506.
8. Shibata S, Raubitschek A, Leong L, et al. A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res (.2009);15:2935.
9. Kraeber-Bode'ré F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (.2006);47:247.
10. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer (.2002);94:1332.
11. Illidge TM, Bayne M, Brown NS, et al. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood (.2009);113:1412.
12. Linde'n O, Hindorf C, Cavallin-Sta° hl E, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res (.2005);11:5215.
13. Buchsbaum D, Khazaeli MB, Liu T, et al. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49. Cancer Res (.1995);55:5881s.
14. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol (.2008); 20:450.
15. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (.2010);9:767.
16. Huang J, Shibaguchi H, Zhao J, et al. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Anticancer Res (.2006);26:1057.
17. Imakiire T, Kuroki M, Shibaguchi H, et al. Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Int J Cancer (.2004);108:564.
18. Naghibalhossaini F, Ebadi P. Evidence for CEA release from human colon cancer cells by an endogenous GPI-PLD enzyme. Cancer Lett (.2006);234:158.
19. Sakahara H, Endo K, Nakashima T, et al. Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against alpha-Fetoprotein. J Nucl Med (.1985);26:750.
20. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-Targeted therapy. J Natl Cancer Inst (.2007);99:694.
21. Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with yttrium-90. J Nucl Med (.1985);26:503.
22. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistributions of yttrium-And indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med (.1989);30:672.
23. Bienert M, McCook B, Carr BI, et al. 90Y microsphere treatment of unresectable liver metastases: Changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging (.2005);32:778.
24. Weber WA. Assessing tumor response to therapy. J Nucl Med (.2009);50:1S.
25. Violet JA,Dearling JL, Green AJ, et al. Fractionated 131I anti-CEA radioimmunotherapy: Effects on xenograft tumour growth and haematological toxicity in mice. Br J Cancer (.2008);99:632.
26. Parry R, Schneider D, Hudson D, et al. Identification of a novel prostate tumor target, mindin/RG-1, for antibodybased radiotherapy of prostate cancer. Cancer Res (.2005);65: 8397.
27. Yoshioka H, Yamamoto S, Hanaoka H, et al. In vivo therapeutic effect of CDH3/P-cadherin-Targeting radioimmunotherapy. Cancer Immunol Immunother (.2012);61:1211.
28. Jacene HA, Filice R, Kasecamp W, et al. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J NuclMed (.2009);50:8.
29. Storto G, De Renzo A, Pellegrino T, et al. Assessment of metabolic response to radioimmunotherapy with 90Yibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Radiology (.2010);254:245.
30. Wong JY, Shibata S, Williams LE, et al. A Phase I trial of 90Y-Anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res (.2003);9:5842.
31. Kramer EL, Liebes L, Wasserheit C, et al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res (.1998);4:1679.
32. Gulec SA, Cohen SJ, Pennington KL, et al. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: A phase I single-dose escalation trial. Clin Cancer Res (.2011);17:4091.